Barbara Ann Sherry

US Patent:

58403051, Nov 24, 1998

Filed:

Mar 14, 1996

Appl. No.:

8/615933

Inventors:

Michael Bukrinsky - Glenwood Landing NY
Barbara A. Sherry - New York NY
Peter C. Ulrich - Old Tappan NJ
Anthony Cerami - Shelter Island NY

Assignee:

The Picower Institute for Medical Research - Manhasset NY

International Classification:

A61K 39395
C07K 1628

US Classification:

4241521

Abstract:

The present invention relates to therapeutic modalities and pharmaceutical compositions for the treatment of HIV-infection using cyclophilin A and its corresponding human cellular binding partner or receptor as a target for intervention. The present invention relates to the use of exogenous or engrafted sources of cyclophilins, anti-cyclophilin antibodies, cyclophilin decoys, soluble forms of cyclophilin-binding partners and small molecules which are supplied extracellularly, and act presumably by interrupting the binding of cyclophilin A with its cellular binding partner(s) or receptor(s) as a treatment for HIV-infection. The present invention further relates to the use of forms of cyclosporin A that have been derivatized by bulky or charged substituents to inhibit cellular uptake and minimize their immunosuppressive activities, which presumably act to disrupt cyclophilin binding to its cellular receptor, likewise as a treatment for HIV-infection. The present invention further relates to genetic constructs to interfere with production and release of cyclophilin and its cognate cellular binding partner(s), to treat HIV-infection. The present invention further relates to screening assays for the identification of compounds which inhibit the interaction of cyclophilin and its cellular receptor.

US Patent:

51456761, Sep 8, 1992

Filed:

Feb 7, 1991

Appl. No.:

7/652198

Inventors:

Thomas J. Fahey - New York NY
Barbara A. Sherry - New York NY
Anthony Cerami - Shelter Island NY

Assignee:

The Rockefeller University - New York NY

International Classification:

A61K 3700

US Classification:

424 851

Abstract:

The present invention relates to the treatment of wound healing dysfunction by the administration of one or more would healing modulators. The wound healing modulator may be selected from appropriate wound healing agents and binding partners, and particularly agents that enhance wound healing. The agent may comprise a cytokine, or mixture of cytokines that are also capable of binding to heparin, and inducing localized inflammation characterized by polymorphonuclear cell infiltration when administered subcutaneously. Particular agents comprise the inflammatory cytokines MIP-1, MIP-1. alpha. , MIP-1. beta. and MIP-2. Diagnostic and therapeutic utilities are proposed, and pharmaceutical compositions are likewise set forth.